신신제약

002800KOSDAQ의약품 제조업

59.4 / 100

Reference Date: 2026-06-10

Financial Score32.0 / 40

News Sentiment13.4 / 25

Momentum4.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health and ROE significantly exceeds the industry average is also solid. Plunged 18.7% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

Shinshin Pharmaceutical specializes in manufacturing and selling OTC medications, particularly topical products for muscle and joint pain. The company primarily sells to pharmacies and wholesale distributors, maintaining direct sales with over 12,000 pharmacies nationwide and actively expanding exports, especially to Southeast Asia.

Number of Employees

369people

Average Salary

59.9M KRW

Score Calculation Basis

Detailed Financial Score

PER

7.31Industry Average 11.936.5Point

Lower than industry avg (good)

PBR

0.91Industry Average 0.892.5Point

Higher than industry avg (caution)

ROE

13.25Industry Average 4.017.0Point

3.3x industry avg (excellent)

Debt Ratio

3.51Industry Average 12.438.0Point

Half of industry avg (excellent)

Trend 2023~20258.0 / 10 points

Revenue Growth Rate

2.0 / 3

Avg ▲5.3% (2-year basis)

Operating Profit Growth Rate

3.0 / 3

Avg ▲35.7% (2-year basis)

ROE Trend

3.0 / 4

Avg ROE 9.5% (improving, 3yr)

Detailed News Sentiment

4 totalPositive 1Neutral 2Negative 1Average Sentiment Score 53.8

Neutral
[바이오스냅] 식약처, 의약품 중 불순물 저감화 사례집 발간
신신제약 관련 바이오스냅의 식약처 사례집 발간은 직접적인 영향이 미미해 중립적 평가.
Positive
신신제약 신신파스 아렉스, K-BPI 소염진통제 부문 8년 연속 1위
신신제약의 신신파스 아렉스가 K-BPI 소염진통제 부문에서 8년 연속 1위를 차지하며 브랜드 경쟁력을 입증했다.
Negative
신신제약, UIP620 및 SS262 치료제 임상 조기종료 결정
신신제약의 주요 치료제 임상 시험 조기 종료로 인해 주가에 부정적 영향 예상.

Detailed Momentum

52-week position1.0Point

Near 52w low (0%, downtrend)

Current 4,480Won52-week high 6,63052-week low 4,480

1-month return0.0Point

1m -18.69% (strong drop)

Volume trend3.0Point

Volume flat

Detailed Disclosure

3 totalPositive 0Neutral 3Negative 0

Neutral투자판단관련주요경영사항(임상시험계획자진취하등) (불면증 환자의 단기치료제 SS262의 제1상 임상시험 조기종료)2026-05-22
Neutral투자판단관련주요경영사항(임상시험계획자진취하등) (과민성 방광 치료제 UIP620의 제3상 임상시험 조기종료)2026-05-22
Neutral분기보고서 (2026.03)2026-05-15